CIK: 1339901 - Address: C/O An2 Therapeutics, Inc., 1800 El Camino Real, Suite D, Menlo Park, CA 94027
8 results

TC

Stat

Stk

Ins

Fil

+d

+w

+m

+q

+h

+y

avg

S%ret112-22-102-10-6-4
S%wins5001005010010067

Filing Date

T Date

Ticker

Issuer

Inc

Sector

Ind

Industry

Owner

oSt

Rel

Title

T

TVal

Price

L

Qty

oc

Own

H

r2y

r1y

r6m

r3m

r6w

r3w

r7d

r3d

f1d

f1w

f1m

f3m

f6m

f1y

8/16/18 17:00
8/15/18
SGYPSynergy Pharmaceuticals, Inc.DEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNYDM.d1801.20015048D
5/29/18 17:03
5/25/18
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDM.d13718.30081653D
5/29/18 17:03
5/25/18
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDS.d-24232.200-8-1253D
5/25/17 17:08
5/23/17
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDM.d14719.60081850D
5/26/16 17:43
5/24/16
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDM.d27918.6032156339D3435-11141064212-115-1
5/26/16 17:43
5/24/16
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDS.d-55537.0032-15-2839D3435-11141064212-115-1
9/2/15 18:43
8/31/15
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDM.d41720.87332010539D3056374021343229-42-8-1-19-6
9/2/15 18:43
8/31/15
MDCOMedicines Co /deDEHealthDrugPharmaceutical PreparationsSpigelman Melvin KNJDS.d-81040.5033-20-3439D3056374021343229-42-8-1-19-6

DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top

Contact